SPRINGDALE, Ark.--(BUSINESS WIRE)--NOWDiagnostics, Inc. (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostic tests, today announced that Labcorp, a global leader of innovative and comprehensive laboratory services, will be the exclusive U.S. distributor of its First To Know® Syphilis Test in professional and healthcare settings.

。

Through Labcorp’s extensive distribution network and trusted presence in clinical settings, this collaboration will expand access to the syphilis test that provides results in 15 minutes with as little as a drop of blood. Labcorp plans to offer the test to professionals and hospital settings by the end of 2024 and directly to patients through Labcorp OnDemand in 2025..

通过Labcorp广泛的分销网络和在临床环境中的可靠存在，这项合作将扩大梅毒检测的范围，该检测只需一滴血即可在15分钟内提供结果。Labcorp计划在2024年底前向专业人员和医院环境提供该测试，并在2025年通过Labcorp OnDemand直接向患者提供。。

“Our collaboration with Labcorp marks a pivotal moment for NOWDx as we scale up access to our First To Know® Syphilis Test across the U.S.,” said Rob Weigle, CEO of NOWDx. “Labcorp’s confidence in our patented touch-to-test technology, along with their longstanding relationships in professional and hospital settings, ensures this critical diagnostic tool is available to more clinicians.

NOWDx首席执行官罗伯·威格尔（RobWeigle）表示：“我们与Labcorp的合作标志着NOWDx的一个关键时刻，因为我们在全美范围内扩大了我们的第一个已知梅毒测试。”。“Labcorp对我们获得专利的触摸测试技术的信心，以及他们在专业和医院环境中的长期关系，确保了更多临床医生可以使用这种关键的诊断工具。

Our retail and public health efforts, which will be announced shortly, alongside Labcorp’s initiatives in the professional and hospital settings, will increase access to testing. This will help support earlier detection and treatment as we address the concerning rise in syphilis cases by providing high-quality, easy-to-use diagnostics.'.

不久将宣布我们的零售和公共卫生工作，以及Labcorp在专业和医院环境中的举措，将增加检测的机会。这将有助于支持早期发现和治疗，因为我们通过提供高质量，易于使用的诊断方法来解决梅毒病例的增加。

Syphilis cases in the U.S. have increased by 80% since 2018, affecting over 207,000 people, including more than 3,700 newborns in 2022. As one of the fastest-growing sexually transmitted infections (STIs) in the U.S., syphilis can cause severe complications if untreated, including blindness, paralysis, and organ damage.

自2018年以来，美国的梅毒病例增加了80%，影响了207000多人，其中2022年有3700多名新生儿。梅毒是美国增长最快的性传播感染之一，如果不及时治疗，可能会导致严重的并发症，包括失明、瘫痪和器官损伤。

When transmitted during pregnancy, it can lead to miscarriage or infant death. Often, those with syphilis do not notice symptoms..

当在怀孕期间传播时，它可能导致流产或婴儿死亡。梅毒患者通常不会注意到症状。。

“NOWDx’s innovative testing technology is a valuable addition to our syphilis portfolio, and we are pleased to work with them to expand access to the First To Know® Syphilis Test,” said Dr. Brian Caveney, Chief Medical and Scientific Officer at Labcorp. “With syphilis cases rising nationwide, we see a pressing need for accessible testing solutions that empower providers and patients on the path to treatment.”.

Labcorp首席医学和科学官Brian Caveney博士说：“NOWDx的创新检测技术是我们梅毒产品组合的宝贵补充，我们很高兴与他们合作，扩大首次了解®梅毒检测的机会。”。“随着梅毒病例在全国范围内的增加，我们迫切需要可获得的检测解决方案，使提供者和患者能够在治疗的道路上获得权力。”。

This collaboration underscores Labcorp and NOWDx’s shared commitment to providing better diagnostic options and improving health outcomes nationwide. Labcorp will also be the U.S. distribution partner for the ADEXUSDx® hCG test currently utilized in hospital settings.

。Labcorp还将成为目前在医院环境中使用的ADEXUSDx®hCG测试的美国分销合作伙伴。

For more information about NOWDx and its full suite of diagnostic solutions, please visit www.nowdx.com.

有关NOWDx及其全套诊断解决方案的更多信息，请访问www.NOWDx.com。

About First To Know® Syphilis Test

About First To Know®梅毒检测

The First To Know® Syphilis Test is a patented buffer-less lateral flow device that provides a qualitative rapid membrane immunochromatographic assay for detecting Treponema pallidum (syphilis) antibodies in human whole blood (capillary) from individuals suspected of having a syphilis infection. First to Know® received marketing authorization from the FDA through the de novo pathway recognizing it as a novel device for syphilis testing in the United States, distinguishing it from other products on the market.

First To Know®梅毒测试是一种获得专利的无缓冲液侧流装置，可提供定性快速膜免疫色谱分析，用于检测疑似梅毒感染者的人全血（毛细血管）中的梅毒螺旋体（梅毒）抗体。First to Know®通过从头途径获得了FDA的上市授权，将其视为美国梅毒检测的新型设备，将其与市场上的其他产品区分开来。

In a clinical study of 1,270 people, the NPA (negative percent agreement) was 99.5%, meaning it correctly identified 99.5% of negative specimens; the PPA (positive percent agreement) was 93.4%, meaning it correctly identified 93.4% of positive specimens when compared to three FDA cleared laboratory tests.

在一项针对1270人的临床研究中，NPA（阴性百分比一致性）为99.5%，这意味着它正确识别了99.5%的阴性标本；PPA（阳性百分比协议）为93.4%，这意味着与三项FDA批准的实验室测试相比，它正确识别了93.4%的阳性标本。

Results from the First to Know® Syphilis Test alone are not sufficient to diagnose syphilis infection and should be followed by additional testing to confirm a diagnosis of syphilis. For more information, visit www.firsttoknow.com..

仅从First to Know®梅毒检测结果不足以诊断梅毒感染，应随后进行额外检测以确认梅毒的诊断。有关更多信息，请访问www.firsttoknow.com。。

About NOWDiagnostics (NOWDx)

关于NOWDiagnostics（NOWDx）

NOWDx develops and manufactures over-the-counter (OTC) and point-of-care (POC) diagnostic tests. Its patented approach enables virtually any immunological assay to be accurately performed onsite in one step using a small amount of capillary blood, yielding results in minutes. With over 75 patents issued and pending, NOWDx's First To Know® and ADEXUSDx® product lines are available in markets worldwide.

NOWDx开发和制造非处方药（OTC）和即时护理（POC）诊断测试。它的专利方法几乎可以使用少量毛细血管血一步在现场准确进行任何免疫学检测，几分钟内即可产生结果。NOWDx的首个Know®和ADEXUSDx®产品线已在全球市场上推出，拥有75多项已发布和正在申请的专利。

Founded in 2013, with headquarters and manufacturing in Springdale, Arkansas, NOWDx envisions a world where people have greater access to in-home testing with results in minutes. The company’s investors include Kompass Kapital Management, DigitalDx Ventures and the Labcorp Venture Fund. NOWDx is committed to changing healthcare by providing accessible, affordable, and accurate testing for all.

NOWDx成立于2013年，总部和生产基地位于阿肯色州的斯普林代尔，它设想了一个世界，在这个世界上，人们可以在几分钟内获得更多的家庭测试结果。该公司的投资者包括Kompass Kapital Management、DigitalDx Ventures和Labcorp风险基金。NOWDx致力于通过为所有人提供可访问、负担得起和准确的测试来改变医疗保健。

Please visit nowdx.com for more information..

有关更多信息，请访问nowdx.com。。

About Labcorp

关于Labcorp

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities.

Labcorp（纽约证券交易所代码：LH）是创新和综合实验室服务的全球领导者，可帮助医生、医院、制药公司、研究人员和患者做出明确而自信的决定。我们通过无与伦比的诊断和药物开发实验室能力，为改善健康和改善生活提供见解和先进科学。

The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for 84% of the new drugs and therapeutic products approved in 2023 by the FDA and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com..

该公司拥有67000多名员工，为大约100个国家的客户提供服务，为2023年FDA批准的84%的新药和治疗产品提供支持，并为世界各地的患者进行了超过6亿次测试。有关我们的更多信息，请访问www.labcorp.com。。